id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-319091-hkuc2xqm	Loscocco, Giuseppe G.	Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19	2020-05-30		.txt	text/plain	617	33	44	In a Letter to the Editor published online on May 12 on International Journal of Hematology [1] , Prof Takami exposed, competently, the possibility to treat secondary hemophagocytic lymphohistiocytosis (sHLH) in COVID-19 patients with low-dose etoposide. The main point, as speculated by the author, is the potential use of low-dose etoposide to restore immunological homeostasis by depleting activated Cytotoxic T lymphocytes (CTLs) and suppressing their production of inflammatory cytokines, which reduces the activity of macrophages and leads to the elimination of activated macrophages and SARS-CoV-2-infected cells by newly activated CTLs. This interesting hypothesis is based (as written by the author) on a recent report by Mehta and colleagues [2] in which "all 35 patients with severe COVID-19 showed hemophagocytosis on bone marrow (BM) aspirates, cytopenia of two or more lineages, and increased serum ferritin levels (≥ 2000 ng/mL)". Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19	./cache/cord-319091-hkuc2xqm.txt	./txt/cord-319091-hkuc2xqm.txt